Published in JAMA · View the paper (DOI)
A study published in JAMA found that drugs granted accelerated FDA approval often relied on nonrandomized studies and surrogate measures to confirm efficacy, with many lacking statistically detectable differences in design features between pre- and post-approval trials. Despite positive results from postmarketing studies, clinical bene...
Coverage from 2 institutions